Evidence map›Paper›PMID 21493740›Full record

Trial reportClinical journal of the American Society of Nephrology : CJASN2011

Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Yuji Takatori, Shigeru Akagi, Hitoshi Sugiyama, Junko Inoue, Shoichiro Kojo, Hiroshi Morinaga, Kazushi Nakao, Jun Wada, Hirofumi Makino

Abstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 90 citations in OpenAlex.

  1. Biocompatible dialysis fluids for peritoneal dialysis.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.Journal of the American Society of Nephrology : JASN · 2013
    Trial
  7. Review
  8. Review
  9. Mass-Spectrometry-Based Research of Cosmetic Ingredients.Molecules (Basel, Switzerland) · 2024
    Review
  10. Article
  11. Article
  12. Five Things to Know About Volume Overload in Peritoneal Dialysis.Canadian journal of kidney health and disease · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. A Patient on Peritoneal Dialysis with Refractory Volume Overload.Clinical journal of the American Society of Nephrology : CJASN · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuji TakatoriDepartment of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Shigeru Akagi
Hitoshi Sugiyama
Junko Inoue
Shoichiro Kojo
Hiroshi Morinaga
Kazushi Nakao
Jun Wada
Hirofumi Makino
Okayama University · JPOkayama University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere are still controversies whether peritoneal dialysis (PD) with icodextrin preserves residual renal and peritoneal membrane functions in patients with diabetes. However, there are no randomized controlled and long-term clinical trials in newly started PD patients with diabetic nephropathy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Forty-one patients with diabetic nephropathy with ESRD were enrolled and randomly assigned to the glucose group (GLU) treated with 8 L of 1.5% or 2.5% glucose or an icodextrin group (ICO) treated with 1.5 or 2.0 L of 7.5% icodextrin-containing solutions. Technique failure, body fluid management, glucose and lipid metabolism, and residual renal and peritoneal functions and were evaluated over 2 years.

resultsThe technique survival rate was 71.4% in ICO and 45.0% in GLU, with most of the technique failure due to volume overload. ICO showed significantly better cumulative technique survival. Net ultrafiltration volume was significantly higher in ICO throughout the study period. There were no beneficial effects of icodextrin on hemoglobin A1c, glycoalbumin, and lipid profile at 24 months. Urine volume and residual renal function declined faster in ICO, but there were no significant differences between the two groups. For peritoneal function, no differences were observed in dialysis-to-plasma creatinine ratios during the observation.

conclusionsIn PD therapy for diabetic nephropathy, the use of icodextrin-containing solutions has a beneficial effect on technique survival, but there are no apparent benefits or disadvantages in residual renal and peritoneal functions compared with conventional PD with glucose solution.

Indexed as

Peritoneal DialysisWater-Electrolyte BalanceAgedBiomarkersBlood GlucoseBody WeightCreatinineDiabetic NephropathiesDialysis SolutionsFemaleGlucansGlucoseGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, AdvancedHumansBiomarkersBlood GlucoseCreatinineDialysis SolutionsGlucansGlucoseGlycated HemoglobinGlycated Serum AlbuminGlycation End Products, Advancedhemoglobin A1c protein, humanIcodextrinLipidsSerum Albumin

Identifiers

PMID21493740
PMCPMC3109930
OpenAlexW2135856930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.